Clinical trial
HuMax-CD20 in Chronic Lymphocytic Leukemia
NCT00093314 · GlaxoSmithKline, Industry · Withdrawn
Key facts
| NCT number | NCT00093314 |
|---|---|
| Title | HuMax-CD20 in Chronic Lymphocytic Leukemia |
| Official title | An Open-labeled, International, Multicenter, Dose Escalating, Phase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | HuMax-CD20 |
| Enrollment | 0 |
| Start date | Oct 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Oct 8, 2004 |
| Last update posted | Apr 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: